The Innovative Medicines Initiative has stated that it grants no Horizon 2020 funding to large pharmaceutical companies, after being accused of serving the interests of big business.
The IMI has been criticised after an investigation by media outlets including the German newspaper Spiegel and the Belgian newspaper De Standaard, which studied the initiative’s procedures and finances for six months. The group concluded that IMI has used €2.5 billion of EU funds to “almost exclusively” benefit the pharmaceutical industry.
According to Spiegel, the IMI is prioritising research projects that benefit the industry instead of focusing on the World Health Organisation’s priorities. In a series of articles published on 9 March, the newspaper also criticises IMI for limiting the influence of universities and small enterprises’ on the initiative’s agenda.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.